What is William Blair's Forecast for Amgen FY2025 Earnings?

Key Points

• William Blair has raised its FY2025 earnings per share forecast for Amgen to $20.86, an increase from the previous estimate of $20.71, indicating strong performance expectations for the biotechnology company.
• Amgen reported earnings of $6.02 per share for the last quarter, significantly exceeding analysts' estimates of $5.28, alongside revenues of $9.18 billion, which surpassed expectations as well.
• The company has declared a quarterly dividend of $2.38 per share, reflecting a 3.3% dividend yield, and will be paid to investors of record on August 22nd.

Amgen Inc. (NASDAQ:AMGN - Free Report) - Equities research analysts at William Blair increased their FY2025 earnings per share estimates for shares of Amgen in a research report issued to clients and investors on Wednesday, August 6th. William Blair analyst M. Phipps now forecasts that the medical research company will earn $20.86 per share for the year, up from their prior estimate of $20.71. William Blair has a "Outperform" rating on the stock. The consensus estimate for Amgen's current full-year earnings is $20.62 per share. William Blair also issued estimates for Amgen's FY2026 earnings at $22.58 EPS, FY2027 earnings at $23.47 EPS, FY2028 earnings at $23.89 EPS and FY2029 earnings at $25.63 EPS.

Amgen (NASDAQ:AMGN - Get Free Report) last posted its earnings results on Tuesday, August 5th. The medical research company reported $6.02 earnings per share for the quarter, topping analysts' consensus estimates of $5.28 by $0.74. Amgen had a net margin of 18.96% and a return on equity of 180.66%. The firm had revenue of $9.18 billion for the quarter, compared to analysts' expectations of $8.86 billion. During the same quarter in the previous year, the firm posted $4.97 earnings per share. The company's revenue was up 9.4% on a year-over-year basis.

Other equities research analysts have also issued research reports about the stock. Royal Bank Of Canada decreased their price target on shares of Amgen from $324.00 to $320.00 and set an "outperform" rating for the company in a research note on Friday, May 2nd. UBS Group dropped their price objective on shares of Amgen from $326.00 to $317.00 and set a "neutral" rating for the company in a report on Wednesday. Cantor Fitzgerald restated a "neutral" rating and issued a $305.00 price objective on shares of Amgen in a research report on Tuesday, June 24th. Guggenheim began coverage on shares of Amgen in a research note on Tuesday, May 20th. They issued a "neutral" rating and a $288.00 target price on the stock. Finally, Mizuho raised their price objective on shares of Amgen from $235.00 to $280.00 and gave the company a "neutral" rating in a research report on Wednesday, May 7th. Two analysts have rated the stock with a sell rating, twelve have given a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Amgen currently has an average rating of "Hold" and an average price target of $307.23.

Amgen Price Performance

Shares of NASDAQ AMGN opened at $287.97 on Thursday. The company has a current ratio of 1.17, a quick ratio of 0.88 and a debt-to-equity ratio of 8.70. Amgen has a 1-year low of $253.30 and a 1-year high of $339.17. The firm has a market capitalization of $154.85 billion, a P/E ratio of 23.45, a P/E/G ratio of 2.60 and a beta of 0.49. The firm's 50-day moving average price is $293.18 and its 200-day moving average price is $292.39.

Institutional Trading of Amgen

Several institutional investors and hedge funds have recently modified their holdings of the business. Capital World Investors boosted its holdings in shares of Amgen by 1,292.0% in the 4th quarter. Capital World Investors now owns 6,495,710 shares of the medical research company's stock valued at $1,693,042,000 after buying an additional 6,029,058 shares during the period. GAMMA Investing LLC increased its stake in Amgen by 43,573.5% in the 1st quarter. GAMMA Investing LLC now owns 3,661,589 shares of the medical research company's stock valued at $1,140,768,000 after buying an additional 3,653,205 shares during the period. Capital International Investors boosted its holdings in shares of Amgen by 40.1% during the 4th quarter. Capital International Investors now owns 12,212,065 shares of the medical research company's stock worth $3,182,843,000 after buying an additional 3,495,503 shares during the period. Nuveen LLC bought a new stake in Amgen in the 1st quarter valued at $688,868,000. Finally, Northern Trust Corp boosted its position in shares of Amgen by 15.8% during the 4th quarter. Northern Trust Corp now owns 6,431,029 shares of the medical research company's stock valued at $1,676,183,000 after acquiring an additional 875,254 shares in the last quarter. Hedge funds and other institutional investors own 76.50% of the company's stock.

Insider Buying and Selling at Amgen

In related news, SVP Rachna Khosla sold 1,500 shares of the stock in a transaction that occurred on Thursday, June 5th. The shares were sold at an average price of $289.68, for a total transaction of $434,520.00. Following the completion of the transaction, the senior vice president owned 8,162 shares of the company's stock, valued at approximately $2,364,368.16. This trade represents a 15.52% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 0.76% of the stock is currently owned by company insiders.

Amgen Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, September 12th. Investors of record on Friday, August 22nd will be given a dividend of $2.38 per share. This represents a $9.52 annualized dividend and a dividend yield of 3.3%. The ex-dividend date is Friday, August 22nd. Amgen's dividend payout ratio is 77.84%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.